# SEXUAL & REPRODUCTIVE HEALTH SELF-CARE MEASUREMENT TOOL

### **FIRST EDITION**

FEBRUARY 2023



# SEXUAL & REPRODUCTIVE HEALTH (SRH) SELF-CARE MEASUREMENT TOOL 2023

This tool was developed by the Evidence and Learning Working Group (ELWG) of the <u>Self-Care</u> <u>Trailblazer Group</u> (SCTG), a global coalition hosted by Population Services International (PSI) dedicated to advancing the policy and practice of safe and effective self-care.

# AUTHORSHIP

This tool is the product of the combined efforts of multiple parties, including:

**Strategic leadership:** Claire Watt Rothschild (PSI) and Gilda Sedgh (Independent).

**Oversight and reviews:** Tool development committee members, Martha Brady (Independent); Caila Brander (Ibis Reproductive Health); Aurélie Brunie (FHI 360); Holly Burke (FHI 360); Jane Cover (PATH); Austen El-Osta (SCARU / Imperial College London); Caitlin Gerdts (Ibis Reproductive Health); Kelsey Holt (UCSF); Karin Hatzold (PSI); Dinesh Kumar (Dr. Rajendra Prasad Government Medical College, Himachal Pradesh); Kristen Little (PSI); Fredrick Makumbi (Makerere University School of Public Health); Saumya RamaRao (Population Council). **Indicator selection:** Intervention leads and presenters, Phil Anglewicz (Johns Hopkins University); Helen Anyasi (FHI 360 Nigeria); Sarah Baum (Ibis Reproductive Health); Caitlin Corneliess (PATH Access Collaborative); Jane Cover (PATH); Ijeoma Egwuatu (GIWYN); Austen El-Osta (SCARU / Imperial College London); Caitlin Gerdts (Ibis Reproductive Health); Karin Hatzold (PSI); Kelsey Holt (UCSF); Cheryl Johnson (WHO); Heidi Bart Johnston (WHO); Dinesh Kumar (Dr. Rajendra Prasad Government Medical College, Himachal Pradesh); Joseph Larmarange (INED); Moses Muwonge (Samasha Medical Foundation); Allen Namagembe (PATH Uganda); Colleen Oakes (PSI); Funmilola OlaOlorun (EVIHDAF / University of Ibadan); Elizabeth Omoluabi (Akena+ Health); Olive Sentumbwe (WHO Uganda); Arlette Simo Fotso (CEPED).

**Tool development & design:** Impact for Health International, Andrea Cutherell, Justine Fisher, Tabitha Kibuka, and Jaitra Sathyandran.

© Copyright 2023 Self-Care Trailblazer Group CC BY-NC 4.0

### ACKNOWLEDGEMENTS

The authors give thanks to the following people for their significant contributions to this tool:

Insights from more than 70 experts who participated in the MEWG Nov 1-3 2022 meeting, including the following presenters and facilitators: Phil Anglewicz (Johns Hopkins University); Helen Anyasi (FHI 360 Nigeria); Sarah Baum (Ibis Reproductive Health); Martha Brady (Independent Consultant); Holly Burke (FHI 360); Caitlin Corneliess (PATH Access Collaborative); Ijeoma Egwuatu (GIWYN); Cheryl Johnson (WHO); Heidi Bart Johnston (WHO); Dinesh Kumar (Dr. RP Government Medical College, Himachal Pradesh); Joseph Larmarange (INED); Moses Muwonge (Samasha Medical Foundation); Allen

### FUNDING STATEMENT

Support for the development of this tool was provided by the Children's Investment Fund Foundation (CIFF) and the William and Flora Hewlett Foundation. The views and opinions expressed in this tool are those of the authors and not necessarily the views of the Foundations. The funders played no role in the methodology or content included in the tool. Namagembe (PATH); Colleen Oakes (PSI); Funmilola OlaOlorun (EVIHDAF / University of Ibadan); Elizabeth Omoluabi (Akena+ Health); Gilda Sedgh (Independent); Olive Sentumbwe (WHO Uganda); Arlette Simo Fotso (CEPED).

Technical support from session and interventions leads for the MEWG meeting: Aurélie Brunie (FHI 360); Jane Cover (PATH); Austen El-Osta (SCARU / Imperial College London); Caitlin Gerdts (Ibis Reproductive Health); Karin Hatzold (PSI); Kelsey Holt (UCSF); Kristen Little (PSI); Fredrick Makumbi (MakSPH).

Feedback from 12 potential users of the tool through a consultation session in Kenya.

### SUGGESTED CITATION

Rothschild CW, Sedgh G, Cover J, Gerdts C, Hatzold K, Holt K, Brady M, Brunie A, Burke H, Cutherell A, El-Osta A, Kibuka T, Kumar D, Little K, Makumbi F, RamaRao S, Sathyandran J, and the Measurement Expert Working Group of the Self-Care Trailblazer Group. (2023) Sexual and Reproductive Health Self-Care Measurement Tool. Self-Care Trailblazer Group, Washington D.C. doi:10.6084/ m9.figshare.21954377

# TABLE OF CONTENTS

Acronyms & Terminology	05	$\rightarrow$
Introduction	06	$\rightarrow$
Methods and Approach	08	$\rightarrow$
Cross-Cutting Themes	10	$\rightarrow$
Indicators	12	$\rightarrow$
Summary table	12	$\rightarrow$
DMPA-SC	17	$\rightarrow$
HIV self-testing	49	$\rightarrow$
Self-managed abortion	72	$\rightarrow$
Annex 1: Acronyms	95	$\rightarrow$

# ACRONYMS

DMPA-SC	Subcutaneous depot medroxyprogesterone acetate
HIV	Human immunodeficiency virus
КАР	Knowledge, Attitudes and Practices
MEWG	Measurement Expert Working Group
M&E	Monitoring and evaluation
SRH	Sexual and reproductive health
SMA	Self-managed abortion

# TERMINOLOGY

#### SELF-CARE

The World Health Organization (WHO) defines self-care as, "the ability of individuals, families, and communities to promote their own health, prevent disease, maintain health, and to cope with illness and disability with or without the support of a health worker."<sup>1</sup> Self-care interventions are corresponding tools that support individuals, families, and communities to practice evidence-based and effective self-care, and may include health information sources, self-testing, and selfadministration of medications, among others.

#### SELF-MANAGED ABORTION

The practice of abortion by the pregnant person themself, with or without the supervision of a health worker. In this document, we use self-managed abortion to refer to those done in accordance with WHO guidelines.<sup>2</sup>

**HIV SELF-TESTING** 

An HIV diagnostic that can be self-administered through the collection of a saliva, blood or urine sample. Reactive tests require a second laboratory-based test to confirm an HIV diagnosis.

For a list of common self-care terms, please refer to SCTG Common Self-Care Terms Guide.

1: World Health Organization. Self-care interventions for health. https://www.who.int/health-topics/self-care#tab=tab\_1 \* see Annex 1 for a full list of acronyms

#### SELF-INJECTABLE DMPA-SC

A progestin-only hormonal contraceptive injectable designed for subcutaneous administration at 3-month intervals. Unlike intramuscular depot medroxyprogesterone acetate (DMPA-IM), DMPA-SC has been developed specifically for injection by non-medical personnel, including contraceptive users, with or without supervision by a health worker.

<sup>2:</sup> World Health Organization. Abortion care guideline. World Health 2: Organization, 2022. https://apps.who.int/iris/bitstream/handle/10665/349316/9789240039483-eng.pdf

#### FIRST EDITION FEBRUARY 2023

# INTRODUCTION

### BACKGROUND

Measurement of self-care interventions is important for monitoring progress and for strengthening the evidence base for effective programming. While self-care is not a new phenomenon, codified consolidated national and global SRH self-care guidelines are still nascent. Moreover, the very feature that defines self-care makes it hard to track and measure many aspects of the journeys self-carers and self-caregivers undertake: by design, much if not all of a user's self-care experiences take place outside of the formal health system, and are therefore not usually included in routine data collection on health service and outcome indicators.

Established in 2018 with support from the Children's Investment Fund Foundation (CIFF) and the William and Flora Hewlett Foundation, the <u>Self-Care Trailblazer</u> <u>Group</u> (SCTG) was formed as a global coalition with the aim of advancing global and regional advocacy for evidence-based self-care; supporting national governments in institutionalizing self-care in sexual and reproductive health policy and practice; and building a global technical community of practice to advance evidence-based self-care practice and evidence.

To help address the need for pragmatic and standardized SRH self-care measures, the SCTG's Evidence and Learning Working Group set forth to develop a measurement tool for SRH self-care.

#### What is the self-care measurement tool?

This SRH self-care measurement tool is a practical, adaptable resource for self-care stakeholders engaged in monitoring and evaluating SRH self-care programs. The tool also established a process for identifying and building consensus around SRH self-care priority indicators, which may serve as a foundation for future efforts to develop priority indicators across an expanded range of self-care interventions. The authors envision that future updates to the tool will incorporate additional self-care interventions and domains of self-care, as the needs of the community of practice evolve.

#### Who should use this tool?

The tool is intended to be used by ministries of health, implementers, evaluators, and researchers interested in measuring progress toward fulfilling the potential of selfcare, and improving standardization and comparability of priority SRH self-care indicators across varying settings.

#### SCOPE OF THE TOOL

The first iteration of this tool includes indicators specific to *three priority self-care interventions* (self-injectable DMPA-SC, HIV self-testing, and self-managed abortion) across *three domains* (enabling environment; knowledge, attitudes and practices; and service delivery and health outcomes). A total of 69 priority indicators are included in this tool. For each indicator, this tool provides information on its definition, the purpose of the indicator, how it is calculated, relevant data sources, and the frequency of its data collection. We also specify whether the indicator is known to have been used in the field ("established"), and provide examples of where the indicator has been used and how it has been used for decision-making, where known examples exist.

While we present indicators that are specific to the three interventions, we believe that these indicators represent priority measures more broadly, and can be applied to other interventions related to self-administration of a medication, self-injection, self-testing or self-sampling.



#### FIGURE 1: DOMAINS OF SELF-CARE MEASUREMENT

#### Domains of self-care measurement

This tool presents priority indicators for each of three domains, meant to capture distinct levels of the health system environment. This organizing framework draws upon established conceptual models for measurement and programming, including the <u>Family Planning High</u> <u>Impact Practices</u> (HIPS) organizing framework and the <u>Supply-Enabling Environment-Demand (SEED)</u> <u>Model for Family Planning Programming</u> developed by EngenderHealth. For this iteration of the tool, we established the scopes of these domains as follows.

#### **Enabling Environment:**

Aspects of the enabling environment addressed in this tool are the policies, laws, regulations, and regulatory agencies that support or hinder the provision and uptake of self-care methods and services. This measurement domain primarily focuses on measurement of systemslevel factors at the subnational or national levels.

#### Knowledge, Attitudes and Practices (KAP):

This tool focuses on individuals' knowledge of selfcare interventions, attitudes and preferences toward these interventions, self-efficacy related to self-care, and practices regarding how to access and use the interventions.

#### Service Delivery and Health Outcomes:

This domain focuses on availability, quality of both products and service delivery, and uptake and use of self-care services, including facility readiness; health provider knowledge, attitudes, and practices; linkages to facility- or community-based follow-up care; and other health outcomes.

# METHODS & APPROACH

### THE CONSENSUS PROCESS

NOV 2022	DEC 2022	JAN 2023	FEB 2023
Expert working group meeting November 2022	Validation with speakers/ intervention leads December 2022 to January 2023	Consultation process January-February 202	

#### EXPERT WORKING GROUP MEETING

To inform the development of the measurement tool, a 3-day expert working group meeting on self-care measurement was held from Nov 1-3, 2022. The meeting agenda, speakers, and participants' list were developed by the Tool Development Committee, which comprised measurement experts within the SCTG membership. Global experts in each of the measurement domains and self-care interventions were recruited to join the Tool Development Committee. During the meeting, invited experts proposed a minimum set of priority indicators for the three self-care interventions (self-injectable DMPA-SC, HIV self-testing, and self-managed abortion) across three domains (enabling environment; knowledge attitudes and practices (KAP); and service delivery and health outcomes). More than 70 experts including academics, researchers, implementers, policymakers and donors with expertise in the self-care measurement participated. Meeting participants assessed the indicators against three criteria, selected from a broader list of indicator selection criteria developed by USAID: their usefulness, their validity, and the feasibility of collecting the data needed for the measure.<sup>3</sup>

**Usefulness:** The indicator captures information that helps move self-care strategies or programming forward

*Feasibility:* Data for the indicator can be obtained with reasonable and affordable effort

*Validity:* To the extent possible, the indicator has been field-tested or used in practice

To learn more about the expert working group meeting and its outcomes, please find a full summary <u>here</u>.

#### VALIDATION WITH SPEAKERS AND INTERVENTION LEADS

Following the expert working group meeting, the organizers developed a consolidated list of proposed indicators and shared this back with each of the speakers who had proposed the indicators. The speakers in turn coordinated with designated leads within the Tool Development Committee to re-evaluate and refine their proposed indicators based on four key factors: (1) to ensure the proposed indicator is well aligned with the domain definition; (2) to prioritize indicators that were categorized as "high priority" during the expert working group based on their validity, feasibility and usefulness,

3: Data for Impact Project. Selection of Indicators. https://www.data4impactproject.org/prh/overview/selection-of-indicators/ (3) to prioritize routine M&E indicators; and (4) to identify which indicators are relevant to the cross-cutting themes (described further below). Indicator revision was conducted in close consultation with each of the designated leads for the respective self-care intervention (self-injectable DMPA-SC, HIV self-testing, and selfmanaged abortion) within the Tool Development Committee.

#### **USER CONSULTATIONS**

A group key informant interview took place with representatives from the Kenyan Ministry of Health (MOH), the Kenyan National Self-Care Network (NSN), and other advocacy, research, and implementation groups related to the policy and practice of self-care, to ensure the tool meets users' needs. A total of 12 stakeholders participated in the Kenya user consultation in January 2023. Their feedback was used to finalize the tool and inform dissemination efforts.

#### LIMITATIONS OF THE TOOL

This tool was developed using a consensus-driven process. We did not undertake a systematic review of the literature to identify indicators that have been tested or used in the field. Ideally, this tool would be informed by such a review. We instead employed a process that assumed that the meeting presenters and participants were familiar with the literature and indicators in their fields of expertise.

Potential users of this tool should exercise care when adopting the indicators, particularly to ensure that the indicators are suitable for, and appropriately adapted to, the context of proposed use. In particular, efforts to measure activities that are illegal or sensitive (e.g., selfmanaged abortion) may require particular attention to guarantee the safety, privacy, and confidentiality of all those involved in the measurement process. While some of the indicators presented in this tool are well-established and integrated within national health management information systems, others are newly developed or may have been fielded only in limited contexts or settings. These new indicators are included where it was deemed that they present the state-of-theart in measurement of a specific concept for a specific intervention and domain. However, users should be aware that not all proposed indicators have been extensively field-tested or formally validated.

The self-care interventions covered in this report have benefited from varying levels of investment and some have likely received more program support than others. Accordingly, the indicators to support these interventions are also at varying development stages. This is reflected in the uneven number and breadth of indicators across the interventions and domains covered in this report.

Finally, integration of data collection of self-care indicators into routine health data systems is critical for improving harmonization of self-care measures across varying settings as well as increasing data collection on these indicators. But the process of adding indicators to HMIS can be long and costly. Recommendations for how to support the integration of data collection on self-care into data collection systems are beyond the scope of this report.

#### **UPDATING THIS TOOL**

This tool is the first edition, with the intention of updating the tool and priority indicators therein as new evidence emerges, including additional evidence on the performance of the proposed indicators across a variety of contexts. New versions of the tool will be available in the <u>SCTG Resource Library</u> as they become available.

# CROSS-CUTTING THEMES

The following cross-cutting themes were identified as relevant to multiple indicators, self-care interventions, and measurement domains. These themes may indicate areas where further measurement guidance is required to support the development and standardization of indicators and measurement approaches across specific use cases.

#### **PRIVATE SECTOR**

The private sector is a <u>key source</u> of SRH products and services in many settings. The challenge of collecting data from the private sector, including private facilities as well as informal and non-facility service delivery points, is relevant to all three interventions and domains covered in this report.

#### EQUITY

Program and policy goals of achieving equitable access to quality health care, including self-care, call for disaggregation of indicators by population subgroup and for targeted collection of data on marginalized and vulnerable populations. Such considerations apply to the indicators proposed in this tool.

#### WOMEN'S AND GIRLS' EMPOWERMENT

While a variety of measures of women's and girls' empowerment have been developed in the context of SRH, there are few measures specifically developed to assess aspects of empowerment specific to self-care. Further guidance will be required to provide recommendations on validated measures of empowerment, including those related to psychosocial readiness, agency, and decision-making, that are best suited to the measurement of empowerment in the context of self-care.

#### PERSON-CENTERED CARE

Measures of person-centered care specific to self-care interventions are currently limited. Further development of measures that capture users' perceptions of care is critical for understanding when and where self-care interventions are preferred by users, and whether other interventions (such as provider-administered care) are preferred. This is critical for ensuring that health systems do not over-invest in certain self-care options at the expense of other self-care delivery models that may be better aligned with the preferences of specific groups.

#### 11

• •

. . . . . . . .

# SUMMARY INDICATOR TABLE

### SELF-INJECTABLE DMPA-SC INDICATORS

01.	National regulatory approval for DMPA-SC	20	$\rightarrow$
02.	Status of policy that authorizes self-injection of DMPA-SC	21	$\rightarrow$
03.	Status of policy that authorizes CHWs to initiate self-injection	22	$\xrightarrow{\rightarrow}$
04.	Status of policy that authorizes private sector staff to initiate self-injection	23	$\rightarrow$
05.	Self-injectable (SI) services are integrated into costed FP program implementation plans (or a strategy for integration is in place, depending on the planning cycle)	24	$\rightarrow$
06.	DMPA-SC is integrated into national quantification and supply planning calculations/forecasts	25	$\rightarrow$
07.	Procurement systems and annual budgets include provision of self-injectable (SI) materials	26	$\rightarrow$
08.	Temporary or permanent structure with authority, resources and information meets quarterly to coordinate scale-up	27	$\rightarrow$
09.	The routine data collection system (reporting forms and fields) or the national HMIS has been revised to capture mode of administration for DMPA-SC (provider-administered or self-injected)	28	$\rightarrow$
10.	Data on self-injection are recorded in the routine HMIS and can be extracted to review progress with SI scale-up	29	$\rightarrow$
11.	DMPA-SC and self-injection are integrated into the pre-service training curricula for health workers	30	$\rightarrow$
12.	Percentage of women aged 15-49 who have heard of a self-injectable contraceptive	31	$\rightarrow$
13.	Percentage of women aged 15-49 who heard about self-injection from various sources	32	$\rightarrow$

#### Domain:

Enabling Environment

Knowledge, attitudes & practices

•

•

• • •

• •

• •

.

•

14.	Percentage of women aged 15-49 who know where	
	they can obtain a self-injectable contraceptive	33
15.	Percentage of women ever trained in self-injection	34
16.	Among injectable users who are not currently self-injecting, percentage who prefer to be self-injecting	35
17.	Disaggregated by whether trained in SI, percentage of women aged 15-45 who feel confident they could inject themselves or be injected by someone other than a provider with DMPA-SC	36
18.	Among current DMPA-SC users, percentage of women aged 15-19 who self-injected their current method	37
19.	Percentage of women who have ever self-injected, by reason for discontinuation	38
20.	Number and percentage of service delivery points (SDPs) actively offering SI services	39
21.	Number and percentage of DMPA-SC doses provided for self-injection	40
22.	Number and percentage of providers trained to offer self-injection	41
23.	Number and percentage of service delivery points (SDPs) with at least one trained provider	42
24.	Number and percentage of DMPA-SC clients who are self-injecting disaggregated by age and new or returning FP user	43
25.	Percentage of FP providers unwilling to offer DMPA SC for SI to young unmarried clients	44
26.	Number and percentage of facilities with uninterrupted stock of DMPA-SC in the past 3 months	45
27.	Percentage of DMPA-SC units being dispensed to clients for SI	46
28.	Number and percentage of DMPA users ever informed about self-injection by a provider	47
29.	Percentage of clients who report receiving counseling on side effects of DMPA-SC	48

### HIV SELF-TESTING INDICATORS

30.	Number of countries with national policies and implementing HIV self-testing	52
31.	Number of countries with regulations on HIVST	53
32.	Number of HIVST kits procured annually	54
33.	Number of HIVST products listed with WHO prequalification approvals annually	55
34.	Number of countries with at least one HIVST registered annually, disaggregated by product	56
35.	Percentage of people aged 15-49 who have ever heard of HIV self-testing	57
36.	Number of people reached with messages about HIVST	58
37.	Source of last HIVST obtained during the last 12 months	59
38.	Percentage of HIVST users who would recommend HIV self-testing to a friend	60
39.	Number and percentage of users who report willingness to distribute a HIVST to their partner or peer	61
40.	HIVST users stating preference for blood-based or oral fluid-based test kit	62
41.	Percentage of people aged 15-49 who have ever used HIV self-test kits/used HIVST kit in the last 3/6/12 months	63
42.	Percentage of HIVST users who have confidence to perform HIVST	64
43.	Percentage of people who have self-tested at testing sites	65
44.	Percentage of HIVST users who report using at least one other self-care product in the last 6 months	66
45.	Number of HIVST kits distributed	67
46.	Percentage of HTS, ART, PrEP and VMMC clinic attendees using HIVST	68
47.	Number of individuals self-tested for HIV, who screened reactive and who received confirmed positive result through provider RDT testing	69

48.	Number of new positive tests who report self-test use	70	$\rightarrow$
49.	Number of people newly enrolled on antiretroviral therapy who report self-test use	71	$\rightarrow$
SE	LF-MANAGED ABORTION INDICATORS		
50.	Protocols for comprehensive abortion care aligned with global standards are in national medical/treatment guidelines	75	$\rightarrow$
51.	Percentage of accredited educational institutions for all relevant cadres with a competency-based SRHR component in pre-service curricula, consistent with global normative guidance	76	$\rightarrow$
52.	Country has system for in-service competency-based training in comprehensive abortion care (CAC) including SMA, for all recommended cadres of providers, consistent with global normative guidance	77	$\rightarrow$
53.	National Essential Medicines List includes combination mifepristone and misoprostol, or misoprostol and mifepristone as separate presentations	78	$\rightarrow$
54.	Number of quality-assured medical abortion products registered and available	79	$\rightarrow$
55.	Percentage of health providers who know the clinical policies prohibiting reporting of SMA clients to authorities	80	$\rightarrow$
56.	Percentage of individuals who understand what to expect at each step of the self-managed abortion process	81	$\rightarrow$
57.	Percentage of clients who felt prepared for what to do if they experienced warning signs or in the event of complications	82	$\rightarrow$
58.	Percentage of individuals who received quality medications from a reliable source or knew where to obtain them	83	$\rightarrow$
59.	Percentage of respondents who reported that services were affordable	84	$\begin{array}{c} \rightarrow \\ \hline \rightarrow \\ \hline \rightarrow \\ \hline \rightarrow \end{array}$
60.	Percentage of respondents who felt their pain was managed effectively	85	$\rightarrow$
61.	Percentage of respondents who reported feeling prepared to determine if their abortion was complete	86	$\rightarrow$

• •

• •

• • •

•

• •

•

. . . . . .

#### SEXUAL & REPRODUCTIVE HEALTH FIRST EDITION SELF-CARE MEASUREMENT TOOL FEBRUARY 2023

62.	Percentage of respondents who report trusting their provider(s)/ pharmacist(s) to keep their personal information confidential	87	$\rightarrow$
63.	Percentage of respondents who report they were treated with respect at all times	88	$\rightarrow$
64.	Percentage of individuals that do not feel judged for seeking follow up care during/after self-managed abortion	89	$\rightarrow$
65.	Percentage of individuals who desire follow-up care for any reason are able to obtain timely desired care	90	$\rightarrow$
66.	Percentage of SMA users seeking follow-up care who receive appropriate medical treatment	91	$\rightarrow$
67.	Percentage of SMA users who are no longer pregnant	92	$\rightarrow$
68.	Individual has a complete abortion without surgical intervention	93	$\rightarrow$
69.	Proportion of individuals with moderate or severe complications	94	$\rightarrow$

# SELF-INJECTABLE DMPA-SCINDICATORS

SEXUAL & REPRODUCTIVE HEALTH FIRST EDITION SELF-CARE MEASUREMENT TOOL FEBRUARY 2023

# SELF-INJECTABLE DMPA-SC INDICATORS

01.	National regulatory approval for DMPA-SC	20	$\rightarrow$
02.	Status of policy that authorizes self-injection of DMPA-SC	21	$\rightarrow$
03.	Status of policy that authorizes CHWs to initiate self-injection	22	
04.	Status of policy that authorizes private sector staff to initiate self-injection	23	$\rightarrow$
05.	Self-injectable (SI) services are integrated into costed FP program implementation plans (or a strategy for integration is in place, depending on the planning cycle)	24	$\rightarrow$
06.	DMPA-SC is integrated into national quantification and supply planning calculations/forecasts	25	$\rightarrow$
07.	Procurement systems and annual budgets include provision of self-injectable (SI) materials	26	$\rightarrow$
08.	Temporary or permanent structure with authority, resources and information meets quarterly to coordinate scale-up	27	$\rightarrow$
09.	The routine data collection system (reporting forms and fields) or the national HMIS has been revised to capture mode of administration for DMPA-SC (provider-administered or self-injected)	28	$\rightarrow$
10.	Data on self-injection are recorded in the routine HMIS and can be extracted to review progress with SI scale-up	29	$\rightarrow$
11.	DMPA-SC and self-injection are integrated into the pre-service training curricula for health workers	30	$\rightarrow$
12.	Percentage of women aged 15-49 who have heard of a self-injectable contraceptive	31	$\rightarrow$
13.	Percentage of women aged 15-49 who heard about self-injection from various sources	32	$\rightarrow$

#### Domain:

Enabling Environment

Knowledge, attitudes & practices

#### Service delivery & health outcomes

.

• •

•

•

. . . .

• •

14.	Percentage of women aged 15-49 who know where they can obtain a self-injectable contraceptive	33
15.	Percentage of women ever trained in self-injection	34
16.	Among injectable users who are not currently self-injecting, percentage who prefer to be self-injecting	35
17.	Disaggregated by whether trained in SI, percentage of women aged 15-45 who feel confident they could inject themselves or be injected by someone other than a provider with DMPA-SC	36
18.	Among current DMPA-SC users, percentage of women aged 15-19 who self-injected their current method	37
19.	Percentage of women who have ever self-injected, by reason for discontinuation	38
20.	Number and percentage of service delivery points (SDPs) actively offering SI services	39
21.	Number and percentage of DMPA-SC doses provided for self-injection	40
22.	Number and percentage of providers trained to offer self-injection	41
23.	Number and percentage of service delivery points (SDPs) with at least one trained provider	42
24.	Number and percentage of DMPA-SC clients who are self-injecting disaggregated by age and new or returning FP user	43
25.	Percentage of FP providers unwilling to offer DMPA SC for SI to young unmarried clients	44
26.	Number and percentage of facilities with uninterrupted stock of DMPA-SC in the past 3 months	45
27.	Percentage of DMPA-SC units being dispensed to clients for SI	46
28.	Number and percentage of DMPA users ever informed about self-injection by a provider	47
29.	Percentage of clients who report receiving counseling on side effects of DMPA-SC	48

#### **INDICATOR 1 | ENABLING ENVIRONMENT**

#### ✓ ESTABLISHED

# NATIONAL REGULATORY APPROVAL FOR DMPA-SC



#### PURPOSE

Attaining national regulatory approval (NRA) is a prerequisite for the introduction of DMPA-SC (and by extension, selfinjection).



#### HOW IT'S CALCULATED

**Yes/No:** Defined as formal approval for DMPA-SC as indicated by Pfizer registration documentation.



#### DATA SOURCE

Industry reports and documentation (e.g., Pfizer quarterly registration list); In a given country, approved medical products can be identified through the national drug authority.

i D

# EXAMPLE OF USE FOR DECISION MAKING

NRA approval provides a greenlight to pursue introduction, as it indicates the product is high quality, safe, and effective.



#### WHERE IT'S BEING USED

Routine reporting for the DMPA-SC Donor Consortium

AC country briefs (<u>https://fpoptions.</u> <u>org/resource/ac-country-briefs/</u>)

 FREQUENCY

 NON-ROUTINE
 MONTHLY
 QUARTERLY
 ANNUALLY
 BIENNIALLY

#### **INDICATOR 2 | ENABLING ENVIRONMENT**

#### ✓ ESTABLISHED

# STATUS OF POLICY THAT AUTHORIZES SELF-INJECTION OF DMPA-SC



#### PURPOSE

Establishing an enabling environment for scale-up and self-injectables (SI) (Indicator refers to health providers that are approved to train women on SI).

#### DATA SOURCE

National policy documents, meeting minutes/verbal updates from routine meetings, programmatic records, communications with MOH key informants, etc.

i

#### EXAMPLE OF USE FOR DECISION MAKING

This data was used to launch introduction of self-injection outside of a research setting (in many countries).



#### HOW IT'S CALCULATED

**Authorized:** The policy allowing for self-injection of DMPA-SC has been approved.

**In process:** The policy allowing self-injection of DMPA-SC is in the drafting and approval process.

**No policy:** The policy allowing self-injection of DMPA-SC does not currently exist and is not currently being written.




#### WHERE IT'S BEING USED

Routine reporting for the DMPA-SC Donor Consortium

Access Collaborative AC dashboard (<u>https://dashboard.access-</u> <u>collaborative.com</u>)

AC country briefs (<u>https://fpoptions.</u> org/resource/ac-country-briefs/)

Clinton Health Access Initiative (CHAI) policy landscape



#### **INDICATOR 3 | ENABLING ENVIRONMENT**

#### ✓ ESTABLISHED

# STATUS OF POLICY THAT AUTHORIZES CHWs TO INITIATE SELF-INJECTION



#### PURPOSE

Operationalizing alternate cadres can increase access, and leveraging Community Health Workers (CHWs) can help overcome last-mile hurdles and human resource constraints in clinic settings.

#### DATA SOURCE

National policy documents, meeting minutes/verbal updates from routine meetings, programmatic records, communications with MOH key informants, etc.

i

# EXAMPLE OF USE FOR DECISION MAKING

Status of CHW policy was used to inform task-sharing/task-shifting and self-care policies in Nigeria.

MONTHIY



#### HOW IT'S CALCULATED

Authorized: The policy allowing CHWs to initiate (i.e., provide training to) self-injection users has been approved.

**In process:** The policy allowing CHWs to initiate self-injection users is in the drafting and approval process.

**No policy:** The policy allowing CHWs to initiate self-injection users does not currently exist and is not currently being written.

2

#### WHERE IT'S BEING USED

Routine reporting for the DMPA-SC Donor Consortium

AC dashboard (<u>https://dashboard.</u> access-collaborative.com)

AC country briefs (<u>https://fpoptions.</u> org/resource/ac-country-briefs/)



NON-ROUTINE

FREQUENCY

( QUARTERLY

ANNUALLY

BIENNIALLY

#### **INDICATOR 4 | ENABLING ENVIRONMENT**

#### ✓ ESTABLISHED

# STATUS OF POLICY THAT AUTHORIZES PRIVATE SECTOR STAFF TO INITIATE SELF-INJECTION



#### PURPOSE

Expanding to alternate cadres of health providers and channels can greatly increase access to and uptake, by reaching women who tend to rely on the private sector for their contraceptive methods.



#### DATA SOURCE

National policy documents, meeting minutes/verbal updates from routine meetings, programmatic records, communications with MOH, etc.

# i

# EXAMPLE OF USE FOR DECISION MAKING

Status of policy to allow SI initiation through drug shops was used to inform training activities in Uganda.

### \*

#### HOW IT'S CALCULATED

**Authorized:** The policy allowing private sector staff (e.g., pharmacists, drug shop staff, private community health workers, etc.) to initiate (i.e., provide training to) self-injection users has been approved.

**In process:** The policy allowing private sector staff to initiate self-injection users is in the drafting and approval process.

**No policy:** The policy allowing private sector staff to initiate self-injection users does not currently exist and is not currently being written.

2

#### WHERE IT'S BEING USED

Routine reporting for the DMPA-SC Donor Consortium

AC dashboard (<u>https://dashboard.</u> <u>access-collaborative.com</u>)

AC country briefs (<u>https://fpoptions.org/</u> resource/ac-country-briefs/)



#### **INDICATOR 5 | ENABLING ENVIRONMENT**

#### **X** NOT ESTABLISHED

SELF-INJECTABLE (SI) SERVICES ARE INTEGRATED INTO COSTED FP PROGRAM IMPLEMENTATION PLANS (OR A STRATEGY FOR INTEGRATION IS IN PLACE, DEPENDING ON THE PLANNING CYCLE)



#### PURPOSE

Demonstrating commitment to scaling SI as part of method mix/FP program; dedicated budget requires in-depth planning and commitment that can later be utilized for accountability monitoring.



#### HOW IT'S CALCULATED

**Yes/No:** A costed implementation plan that specifically references self-injection has been approved by the MOH.

DATA SOURCE

Key informant interviews with MOH staff.

#### STATUS OF DEVELOPMENT

Access Collaborative includes this indicator in its 'Institutionalization Tracker', which is primarily used internally, to monitor progress with SI scale up across multiple countries.



Q

NON-ROUTINE

FREQUENCY

QUARTERLY

MONTHIY


ANNUALLY

BIENNIALLY

#### **INDICATOR 6 | ENABLING ENVIRONMENT**

#### ✓ ESTABLISHED

# DMPA-SC IS INTEGRATED INTO NATIONAL QUANTIFICATION AND SUPPLY PLANNING CALCULATIONS/FORECASTS



#### **INDICATOR 7 | ENABLING ENVIRONMENT**

#### **X** NOT ESTABLISHED

# PROCUREMENT SYSTEMS AND ANNUAL BUDGETS INCLUDE PROVISION OF SELF-INJECTABLE (SI) MATERIALS



#### PURPOSE

Including client instructions (i.e., job aids) has proved to be instrumental for successful self-injection. Early in the scaling process, countries may rely on projects and NGOs for distribution of these materials. Sustainable scale requires job aid procurement to be integrated into systems and budgets.



#### HOW IT'S CALCULATED

**Yes/No:** Job aids are distributed to facilities as part of the supply chain.

DATA SOURCE

Key informant interviews with MOH staff.



#### STATUS OF DEVELOPMENT

Access Collaborative includes this indicator in its 'Institutionalization Tracker', which is primarily used internally, to monitor progress with SI scale up across multiple countries.



 $\mathbf{O}$ 

NON-ROUTINE

FREQUENCY

QUARTERLY

MONTHIY

ANNUALLY

BIENNIALLY

#### **INDICATOR 8 | ENABLING ENVIRONMENT**

#### X NOT ESTABLISHED

TEMPORARY OR PERMANENT STRUCTURE WITH AUTHORITY, RESOURCES AND INFORMATION MEETS QUARTERLY TO COORDINATE SCALE-UP



#### PURPOSE

Having a clear governance model lends credibility and authority to efforts to scale DMPA-SC and SI; provides a venue for accountability; establishes systematic and coordinated approach to scale-up.



#### HOW IT'S CALCULATED

**Yes/No:** Self-injection scale-up considerations are included on a regular basis in meetings of coordinating committee (e.g., MOG, TWG, and/or task force).

### Q

#### DATA SOURCE

Monthly/bimonthly/quarterly meeting minutes from coordinating body; Key informant interviews with project or MOH staff.



#### STATUS OF DEVELOPMENT

Access Collaborative includes this indicator in its 'Institutionalization Tracker', which is primarily used internally, to monitor progress with SI scale up across multiple countries.



#### **INDICATOR 9 | ENABLING ENVIRONMENT**

#### **X** NOT ESTABLISHED

THE ROUTINE DATA COLLECTION SYSTEM (REPORTING FORMS AND FIELDS) FOR THE NATIONAL HMIS HAS BEEN REVISED TO CAPTURE MODE OF ADMINISTRATION FOR DMPA-SC (PROVIDER-ADMINISTERED OR SELF-INJECTED)



#### PURPOSE

Collecting and reviewing data for course correction is essential for tracking progress of implementation and scale-up of self-injection.



#### HOW IT'S CALCULATED

**Yes/No:** Data collection system for the national HMIS has been revised making it possible to record/capture data on self-injection.



#### DATA SOURCE

Key informant interviews with MOH staff responsible for the HMIS to reveal whether tools have been revised, printed and disseminated.



#### STATUS OF DEVELOPMENT

This indicator is a revision of one reported on by the Access Collaborative in their quarterly SI monitoring reports. It has been broken into two indicators (9 and 10 in this tool) to improve utility.



#### **INDICATOR 10 | ENABLING ENVIRONMENT**

#### **X** NOT ESTABLISHED

### DATA ON SELF-INJECTION ARE RECORDED IN THE ROUTINE HMIS AND CAN BE EXTRACTED TO REVIEW PROGRESS WITH SI SCALE UP



#### PURPOSE

Collecting and reviewing data for course correction is essential for tracking progress with self-injection scale-up.



#### HOW IT'S CALCULATED

**Yes/No:** Data on the mode of administration for DMPA-SC (provider-administered or self-injected) is available for review through the routine HMIS.




#### DATA SOURCE

HMIS data extraction to reveal whether SI data is captured in the routine system.



#### STATUS OF DEVELOPMENT

This indicator is a revision of one reported on by the Access Collaborative in their quarterly SI monitoring reports. It has been broken into two indicators (9 and 10 in this tool) to improve utility.



#### **INDICATOR 11 | ENABLING ENVIRONMENT**

#### **X** NOT ESTABLISHED

DMPA-SC AND SELF-INJECTION ARE INTEGRATED INTO THE PRE-SERVICE TRAINING CURRICULA FOR HEALTH WORKERS



#### PURPOSE

Revising the pre-service training curriculum to institutionalize self-injection.



#### HOW IT'S CALCULATED

**Yes/No:** Pre-service training curriculum has been revised to include DMPA-SC and self-injection.



#### DATA SOURCE

Key informant interviews with MOE and MOH staff.



#### STATUS OF DEVELOPMENT

Access Collaborative includes this indicator in its "Institutionalization Tracker", which is primarily used internally, to monitor progress with SI scale-up across multiple countries.



NON-ROUTINE

FREQUENCY

QUARTERLY

MONTHIY


ANNUALLY

BIENNIALLY

#### **INDICATOR 12 | KAP (KNOWLEDGE)**

#### ✓ ESTABLISHED


## PERCENTAGE OF WOMEN AGED 15-49 WHO HAVE HEARD OF A SELF-INJECTABLE CONTRACEPTIVE



#### **INDICATOR 13 | KAP (KNOWLEDGE)**

#### ✓ ESTABLISHED


# PERCENTAGE OF WOMEN AGED 15-49 WHO HEARD ABOUT SELF-INJECTION FROM VARIOUS SOURCES



#### **INDICATOR 14 | KAP (KNOWLEDGE)**

#### ✓ ESTABLISHED

## PERCENTAGE OF WOMEN AGED 15-49 WHO KNOW WHERE THEY CAN OBTAIN A SELF-INJECTABLE CONTRACEPTIVE



#### **INDICATOR 15 | KAP (KNOWLEDGE)**

#### **X** NOT ESTABLISHED

# PERCENTAGE OF WOMEN EVER TRAINED IN SELF-INJECTION



#### PURPOSE

Understanding accessibility and availability of SI training.



#### HOW IT'S CALCULATED

**Numerator:** Number of women ever trained in SI\*

**Denominator:** Number of women aged 15-49 years

**Calculation:** Numerator ÷ denominator X 100

\*NB: training needs to be clearly defined for the specific context in order to measure this indicator.



#### DATA SOURCE

PMA annual longitudinal female survey (not currently on survey, but in consideration for future).

#### STATUS OF DEVELOPMENT

Not currently in the PMA annual longitudinal female survey, but in consideration for future.



#### **INDICATOR 16 | KAP (ATTITUDES)**

#### **X** NOT ESTABLISHED

# AMONG INJECTABLE USERS WHO ARE NOT CURRENTLY SELF-INJECTING, PERCENTAGE WHO PREFER TO BE SELF-INJECTING

	Ċ
<u> </u>	

#### **PURPOSE**

Gauging interest in self-injectable (SI) contraception among those currently using provideradministered DMPA, as an indication of the gap in the gap in availability or access to self-injection services.



#### HOW IT'S CALCULATED

**Numerator:** Number of women who would prefer to self-inject (SI) if trained

**Denominator:** Number of women using provider-administered DMPA injectable either (SC or IM)

**Calculation:** Numerator ÷ denominator X 100

<b>U</b>	
· · · ·	

#### DATA SOURCE

PMA annual longitudinal female survey (not currently on survey, but in consideration for future).



#### WHERE IT'S BEING USED

The Performance Monitoring for Action (PMA) surveys (<u>https://www.pmadata.</u> <u>org/data/survey-methodology</u>)



NON-ROUTINE

MONTHIY

FREQUENCY

) ( QUART

QUARTERLY

ANNUALLY BIE

BIENNIALLY

#### **INDICATOR 17 | KAP (ATTITUDES)**

#### **X** NOT ESTABLISHED

DISAGGREGATED BY WHETHER TRAINED IN SI, PERCENTAGE OF WOMEN AGED 15-45 WHO FEEL CONFIDENT THEY COULD INJECT THEMSELVES OR BE INJECTED BY SOMEONE OTHER THAN A PROVIDER WITH DMPA-SC



#### PURPOSE

Weighing self-efficacy to self-inject as a precursor to informed decision-making.

0	
X	

#### DATA SOURCE

PMA annual longitudinal female survey (not currently on survey, but in consideration for future).



#### STATUS OF DEVELOPMENT

Not currently in the PMA annual longitudinal female survey, but in consideration for future.



#### HOW IT'S CALCULATED

Numerator: Number of women confident they could inject themselves or be injected by someone other than a provider (e.g., husband, friend, and/or family member)

**Denominator:** Number of women aged 15-49 years (disaggregated by whether trained in SI)

**Calculation:** Numerator ÷ denominator X 100


 Image: Second system
 FREQUENCY

 NON-ROUTINE
 MONTHLY
 QUARTERLY
 ANNUALLY
 BIENNIALLY

## **INDICATOR 18 | KAP (PRACTICES)**

### ✓ ESTABLISHED

# AMONG CURRENT DMPA-SC USER, PERCENTAGE OF WOMEN AGED 15-49 WHO SELF-INJECTED THEIR CURRENT METHOD



## **INDICATOR 19 | KAP (PRACTICES)**

### **X** NOT ESTABLISHED

# PERCENTAGE OF WOMEN WHO HAVE EVER SELF-INJECTED, BY REASON FOR DISCONTINUATION

4	~
	Car
N	

### PURPOSE

Delineating reasons will reveal the proportion of discontinuation that is due to system issues (access, stock, etc.) versus personal preference or other constraints.



### DATA SOURCE

PMA annual longitudinal female survey (not currently on survey, but in consideration for future).



Used to monitor investments in DMPA-SC and SI, by CIFF and BMGF.



### HOW IT'S CALCULATED

**Numerator:** Reason of discontinuation of self-injection (multiple selections allowed)

**Denominator:** Past self-injection users (Women who self-injected previously but not currently)

**Calculation:** Numerator ÷ denominator X 100

2	2	

### WHERE IT'S BEING USED


The Performance Monitoring for Action (PMA) surveys (<u>https://www.pmadata.</u> <u>org/data/survey-methodology</u>)



## INDICATOR 20 | SERVICE DELIVERY AND HEALTH OUTCOMES

### ✓ ESTABLISHED

# NUMBER AND PERCENTAGE OF SERVICE DELIVERY POINTS (SDPs) ACTIVELY OFFERING SI SERVICES



## INDICATOR 21 | SERVICE DELIVERY AND HEALTH OUTCOMES ✓ ESTABLISHED

# NUMBER AND PERCENTAGE OF DMPA-SC DOSES PROVIDED FOR SELF-INJECTION

 $( \bigcirc )$ 

### PURPOSE

Tracking consumption of units for SI purposes is useful for quantification purposes. Note that the number of doses for self-injection should not be used as a target, since self-injection is a client's choice, neither better nor worse than provideradministration (or any other method).



## HOW IT'S CALCULATED

**Numerator:** Number of self-injection doses (including doses given out for home use)

Denominator: Total DMPA-SC doses

**Calculation of percentage:** Numerator ÷ denominator X 100



i

# 

HMIS

## EXAMPLE OF USE FOR DECISION MAKING

Contribute to data-driven quantification with information on self-injection clients who obtain all units for the year in one visit.




### WHERE IT'S BEING USED

National and subnational quarterly reporting for Ugandan MOH.



## INDICATOR 22 | SERVICE DELIVERY AND HEALTH OUTCOMES

# NUMBER AND PERCENTAGE OF PROVIDERS TRAINED TO OFFER SELF-INJECTION



✓ ESTABLISHED

## INDICATOR 23 | SERVICE DELIVERY AND HEALTH OUTCOMES ✓ ESTABLISHED


# NUMBER AND PERCENTAGE OF SERVICE DELIVERY POINTS (SDPs) WITH AT LEAST ONE TRAINED PROVIDER

Ø	<b>PURPOSE</b> Reflecting the operationalization of self- injection or the capacity to offer self- injection services.	Å	HOW IT'S CALCULATED Numerator: Number of service delivery points (SDPs) with at least one trained provider
			<b>Denominator:</b> Total number of service delivery points (SDPs)
			<b>Calculation of percentage:</b> Numerator ÷ denominator X 100
0	DATA SOURCE		
	iHRIS-Human Resources Information System.		WHERE IT'S BEING USED
		8	Human Resources information system: ( <u>http://hris.health.go.ug</u> )
i	EXAMPLE OF USE FOR DECISION MAKING		Routine reporting for the DMPA-SC Donor Consortium
	Track progress with training of providers; identify training gaps.		Access Collaborative dashboard & self-injection quarterly report ( <u>https://dashboard.access-collaborative.com</u> )
	FREQUENCY		
	NON-ROUTINE MONTHLY	QUARTERLY	ANNUALLY BIENNIALLY

## **INDICATOR 24 | SERVICE DELIVERY AND HEALTH OUTCOMES**

#### ✓ ESTABLISHED

NUMBER AND PERCENTAGE OF DMPA-SC CLIENTS WHO ARE SELF-INJECTING, DISAGGREGATED BY AGE AND NEW OR RETURNING FP USER



## **INDICATOR 25 | SERVICE DELIVERY AND HEALTH OUTCOMES**

### ✓ ESTABLISHED

# PERCENTAGE OF FP PROVIDERS UNWILLING TO OFFER DMPA SC FOR SI TO YOUNG UNMARRIED CLIENTS



### PURPOSE

DATA SOURCE

Periodic Mystery Client interactions with at least 2 profiles: young,

married multiparous woman; Client exit interviews to learn if unmarried

to try DMPA-SC and self-injection.

nulliparous unmarried woman vs older,

adolescents are offered the opportunity

Quantifying lack of access to DMPA-SC for self-injection for adolescents. This is a known issue, which merits addressing through periodic (non-routine) investigations.



## HOW IT'S CALCULATED

Numerator: Number of providers unwilling to offer DMPA SC for SI to a young unmarried client (under 18 years old)

Denominator: Total number of FP service providers

NB: This is only meaningful if made in comparison to the older profile (18 and above). The gap between the 2 profiles should be emphasized (rather than just the level for the younger profile by itself).

### Calculation of percentage:

Numerator ÷ denominator X 100



### **EXAMPLE OF USE FOR DECISION MAKING**

Data analyzed, presented and reviewed as part of partner level program reviews and at technical working group meetings.



## **INDICATOR 26 | SERVICE DELIVERY AND HEALTH OUTCOMES** ✓ ESTABLISHED

# NUMBER AND PERCENTAGE OF FACILITIES WITH UNINTERRUPTED STOCK OF DMPA-SC IN THE PAST 3 MONTHS



Q

### PURPOSE

Evaluating the extent to which selfinjection scale-up is hindered by stockouts of DMPA-SC commodities. In the absence of sufficient consistent supply, providers will ration DMPA-SC, limiting the offer of self-injection services.



### HOW IT'S CALCULATED

**Numerator:** Number of facilities with uninterrupted stock of DMPA-SC in the past 3 months

**Denominator:** All facilities offering DMPA-SC

**Calculation of percentage:** Numerator ÷ denominator X 100

DATA SOURCE

HMIS or LMIS data; Periodic provider surveys, PMA.

### EXAMPLE OF USE FOR DECISION MAKING

Data analyzed, presented and reviewed as part of partner level program reviews and at technical working group meetings.

PREQUENCY NON-ROUTINE

MONTHLY

QUARTERLY


(i)

ANNUALLY

BIENNIALLY

## INDICATOR 27 | SERVICE DELIVERY AND HEALTH OUTCOMES ✓ ESTABLISHED

# PERCENTAGE OF DMPA-SC UNITS BEING DISPENSED TO CLIENTS FOR SI



## **INDICATOR 28 | SERVICE DELIVERY AND HEALTH OUTCOMES** × NOT ESTABLISHED

## NUMBER AND PERCENTAGE OF DMPA USERS EVER INFORMED ABOUT SELF-INJECTION BY A PROVIDER



### PURPOSE

Shedding light on whether clients are given the option of self-injection. While having a trained provider and sufficient supply are conditions that make selfinjection possible, it will only be available to people if providers are willing to conduct the training.



### HOW IT'S CALCULATED

**Numerator:** Number of DMPA (IM and SC) clients informed about SI

**Denominator:** Total number of DMPA (IM and SC) clients

**Calculation of percentage:** Numerator ÷ denominator X 100

Q

## DATA SOURCE

Periodic Client Exit surveys or PMA-type surveys.

### EXAMPLE OF USE FOR DECISION MAKING

This indicator has not been widely used, although small surveys are capturing this data to understand whether providers have incorporated SI into informed choice counseling.

Ð

NON-ROUTINE

FREQUENCY

QUAF

MONTHLY

QUARTERLY

i

ANNUALLY

BIENNIALLY

## **INDICATOR 29 | SERVICE DELIVERY AND HEALTH OUTCOMES** × NOT ESTABLISHED

# PERCENTAGE OF CLIENTS WHO REPORT RECEIVING COUNSELING ON SIDE EFFECTS OF DMPA-SC



### PURPOSE

Ensuring comprehensive counseling for side effects. This is critical, ideally at initiation, because self-injectors have few interactions with providers.



## HOW IT'S CALCULATED

**Numerator:** Number of DMPA-SC clients counselled on side effects

**Denominator:** Total number of DMPA-SC clients

**Calculation of percentage:** Numerator ÷ denominator X 100

Q


## DATA SOURCE

Periodic Client Exit surveys or PMA-type surveys.



# EXAMPLE OF USE FOR DECISION MAKING

This indicator is routinely captured in surveys for contraceptive methods (as part of the Method Information Index). Data can be disaggregated by method and mode of administration.



HIV SELF-TESTING INDICATORS SEXUAL & REPRODUCTIVE HEALTH FIRST EDITION SELF-CARE MEASUREMENT TOOL FEBRUARY 2023

# HIV SELF-TESTING INDICATORS

30.	Number of countries with national policies and implementing HIV self-testing	52	$\rightarrow$
31.	Number of countries with regulations on HIVST	53	$\rightarrow$
32.	Number of HIVST kits procured annually	54	$\rightarrow$
33.	Number of HIVST products listed with WHO prequalification approvals annually	55	$\rightarrow$
34.	Number of countries with at least one HIVST registered annually, disaggregated by product	56	$\rightarrow$
35.	Percentage of people aged 15-49 who have ever heard of HIV self-testing	57	$\rightarrow$
36.	Number of people reached with messages about HIVST	58	$\rightarrow$
37.	Source of last HIVST obtained during the last 12 months	59	$\rightarrow$
38.	Percentage of HIVST users who would recommend HIV self-testing to a friend	60	$\rightarrow$
39.	Number and percentage of users who report willingness to distribute a HIVST to their partner or peer	61	$\rightarrow$
40.	HIVST users stating preference for blood-based or oral fluid-based test kit	62	$\rightarrow$
41.	Percentage of people aged 15-49 who have ever used HIV self-test kits/used HIVST kit in the last 3/6/12 months	63	$\rightarrow$
42.	Percentage of HIVST users who have confidence to perform HIVST	64	$\rightarrow$
43.	Percentage of people who have self-tested at testing sites	65	$\rightarrow$
44.	Percentage of HIVST users who report using at least one other self-care product in the last 6 months	66	$\rightarrow$
45.	Number of HIVST kits distributed	67	$\rightarrow$

#### Domain:

Enabling Environment

## Knowledge, attitudes & practices

## Service delivery & health outcomes

. . . .

•

•

• •

• • •

• •


• •

46.	Percentage of HTS, ART, PrEP and VMMC clinic attendees using HIVST	68	$\rightarrow$
47.	Number of individuals self-tested for HIV, who screened reactive and who received confirmed positive result through provider RDT testing	69	$\rightarrow$
48.	Number of new positive tests who report self-test use	70	$\rightarrow$
49.	Number of people newly enrolled on antiretroviral therapy who report self-test use	71	$\rightarrow$

## **INDICATOR 30 | ENABLING ENVIRONMENT**




# NUMBER OF COUNTRIES WITH NATIONAL POLICIES AND IMPLEMENTING HIV SELF-TESTING



## **INDICATOR 31 | ENABLING ENVIRONMENT**

### ✓ ESTABLISHED

# NUMBER OF COUNTRIES WITH REGULATIONS ON HIVST




PURPOSE

## **INDICATOR 32 | ENABLING ENVIRONMENT**

# NUMBER OF HIVST KITS PROCURED ANNUALLY



HOW IT'S CALCULATED



## **INDICATOR 33 | ENABLING ENVIRONMENT**

### ✓ ESTABLISHED

55

# NUMBER OF HIVST PRODUCTS LISTED WITH WHO PREQUALIFICATION APPROVAL ANNUALLY



### PURPOSE

Understanding number of HIVST kits pre-qualified (PQed) or listed by Stringent Regulatory Authority (SRA)/Expert Review Panel for Diagnostics (ERPD).



## HOW IT'S CALCULATED

Number of HIVST products listed with approvals (WHO prequalification) annually.



### DATA SOURCE

WHO PQ reports (WHO PQ, FDA, Global Fund, CE, TGA).



# EXAMPLE OF USE FOR DECISION MAKING

Used to track product landscape.



## WHERE IT'S BEING USED


Collected biannually by WHO.



## **INDICATOR 34 | ENABLING ENVIRONMENT**

### ✓ ESTABLISHED

# NUMBER OF COUNTRIES WITH AT LEAST ONE HIVST REGISTERED ANNUALLY, DISAGGREGATED BY PRODUCT



## **INDICATOR 35 | KAP (KNOWLEDGE)**

### ✓ ESTABLISHED

# PERCENTAGE OF PEOPLE AGED 15-49 WHO HAVE EVER HEARD OF HIV SELF-TESTING

4	-	
	(dk	
Ν.		

### PURPOSE

Facilitating the planning of educational/ awareness campaigns to target particular groups based on reported knowledge gaps or used to measure success of IEC campaigns.

## DATA SOURCE

Primary: National/sub-national surveys.

**Other uses:** Could be collected at a programmatic level through surveys of target population.



Q

## WHERE IT'S BEING USED

HIV self-testing monitoring and evaluation guidance for HIV programmes (psi.org)

DHS



### HOW IT'S CALCULATED

**Numerator:** Number of people reporting they've heard of HIVST (based on the question)

**Denominator:** Number of people in sample

**Calculation of percentage:** Numerator ÷ denominator X 100



### EXAMPLE OF USE FOR DECISION MAKING

Used to target sub-populations with HIVST IEC materials or evaluate the success of awareness building/ demand creation activities.



## **INDICATOR 36 | KAP (KNOWLEDGE)**

### ✓ ESTABLISHED

# NUMBER OF PEOPLE REACHED WITH MESSAGES ABOUT HIVST



### PURPOSE

Measuring demand creation activities.

$\mathbf{O}$	l
<b>U</b>	
	/

## DATA SOURCE

This indicator requires its own indicator reference sheet to define the various channels of demand creation. E.g., online reach data is collected from website/app analytics; and traditional demand creation reach is collected from promoters/community mobilization agent rosters/tally books.

	Ζ
$\sim$	

## WHERE IT'S BEING USED

Indicator has been used by PSI's Strengthening HIVST in the Private Sector (SHIPS) project and is standard across demand creation activities.



## HOW IT'S CALCULATED

Data based on counts of people interacted with or reached via various channels. These can include online channels (website/app impressions and engagements based on web/ app analytics) or traditional demand creation channels such as community mobilization, community activation, or in-store activation (based on registers/ tally books kept by promoters).



# EXAMPLE OF USE FOR DECISION MAKING

Data is used for planning/logistics to compare existing staffing levels to planned reach (are staffing levels appropriate for targets), as well as compared against outcomes such as awareness, use, or sales as a proxy for effectiveness of demand creation activities.



## **INDICATOR 37 | KAP (KNOWLEDGE)**

#### **X** NOT ESTABLISHED

# SOURCE OF LAST HIVST OBTAINED DURING THE LAST 12 MONTHS



### PURPOSE

Understanding where users are obtaining HIVST (which channels)



(i)

### HOW IT'S CALCULATED

Number of people reporting that they obtained the last HIVST used from pharmacies, public health facilities, other retail, a friend, community health worker, etc.).

**EXAMPLE OF USE FOR** 

**DECISION MAKING** 



## DATA SOURCE

National survey (e.g., DHS/AIS).

	<b>STATUS OF DEVELOPMENT</b> This indicator has not been used yet for HIVST, but the same indicator is used for contraceptive methods in DHS.	Data used for targeting demand creation/awareness campaigns. It helps us understand the types of clients who prefer to obtain HIVST from various channels.
Ð	FREQUENCY     NON-ROUTINE     MONTHLY     QL	JARTERLY ANNUALLY BIENNIALLY

## **INDICATOR 38 | KAP (ATTITUDES)**

### ✓ ESTABLISHED

# PERCENTAGE OF HIVST USERS WHO WOULD RECOMMEND HIV SELF-TESTING TO A FRIEND



### PURPOSE

Measuring client satisfaction which covers both their satisfaction with the actual product (ease of use) as well as their satisfaction with the information they received to prepare them to use the product.

## DATA SOURCE

Periodic survey/client satisfaction survey/ exit interview

0

### WHERE IT'S BEING USED

PSI's Strengthening HIVST in the Private Sector (SHIPS) project. Data is collected through opt-in chatbot surveys but could also be collected through a more widespread consumer survey.



### HOW IT'S CALCULATED

**Numerator:** Number of clients who agree that they would recommend HIVST

**Denominator:** Number of people in the sample

**Calculation of percentage:** Numerator ÷ denominator X 100



# EXAMPLE OF USE FOR DECISION MAKING

Most useful when paired with qualitative data (interviews) to understand what consumers like/don't like, so they can be replicated or revised (e.g., the information being provided, how the information is provided, the product itself, and/or some combination).



## **INDICATOR 39 | KAP (ATTITUDES)**

#### **X** NOT ESTABLISHED

## NUMBER AND PERCENTAGE OF USERS WHO **REPORT WILLINGNESS TO DISTRIBUTE A HIVST TO THEIR PARTNER OR PEER**

	-
	((/)
V.	
1	

### PURPOSE

Measuring a similar but slightly different aspect of client satisfaction. Clients wouldn't be willing to distribute HIVST without adequate information about the importance of partner testing as well as their own satisfaction for the product.



### HOW IT'S CALCULATED

Numerator: Number of people who report willingness to distribute HIVST to their partner or peer (sexual partner/ injection user)

Denominator: Number of people in the sample

### Calculation of percentage:

Numerator ÷ denominator X 100

$\sim$	
	Pe

## DATA SOURCE

riod survey.

0
త

### WHERE IT'S BEING USED


Meeting Targets and Maintaining Epidemic Control (EPIC) Project HIV Self Testing Operational Guide (<u>https://www.fhi360.org/</u> sites/default/files/media/documents/epichiv-self-testing-guide.pdf)

**PSI** projects

# *(i)*

**EXAMPLE OF USE FOR DECISION MAKING** 

Most useful when paired with gualitative data to understand the facilitators or barriers to secondary distribution.



## **INDICATOR 40 | KAP (ATTITUDES)**

### ✓ ESTABLISHED

# HIVST USERS STATING PREFERENCE FOR BLOOD-BASED OR ORAL FLUID-BASED TEST KIT

	-
	as
	<b>W</b>
V	

### PURPOSE

Obtaining data helps programmers or governments understand consumer preferences to drive both messaging as well as procurement/stocking (having the preferred types of products at the places preferred by each user group).



### HOW IT'S CALCULATED

The data can be collected routinely through sales/distribution registers or through periodic surveys.

## Q

### DATA SOURCE

Sales/distribution registers (if sales/ distribution includes a choice of products) or through periodic satisfaction or other consumer surveys.



## WHERE IT'S BEING USED

Indicator is collected/analyzed across a variety of PSI projects and included in documented research studies.

# i

### EXAMPLE OF USE FOR DECISION MAKING

Data helps programmers and governments understand consumer preferences to drive both messaging as well as procurement/ stocking (having the preferred types of products at the places preferred by each user group).



## **INDICATOR 41 | KAP (PRACTICES)**

### ✓ ESTABLISHED

## PERCENTAGE OF PEOPLE AGED 15-49 WHO HAVE EVER USED HIV SELF-TEST KITS/USED HIVST KIT IN THE LAST 3/6/12 MONTHS



### PURPOSE

Facilitating the planning of educational/ awareness campaigns to target particular groups based on reported knowledge gaps or used to measure success of IEC campaigns.

## Q

### DATA SOURCE

Primary: National/sub-national surveys.

**Other uses:** Could be collected at a programmatic level through surveys of target population.



## WHERE IT'S BEING USED

HIV self-testing monitoring and evaluation guidance for HIV programmes (psi.org)

DHS



### HOW IT'S CALCULATED

**Numerator:** Number of people reporting ever having used a HIVST kit

**Denominator:** Number of people in the sample

**Calculation of percentage:** Numerator ÷ denominator X 100



Used to target sub-populations with HIVST IEC materials.

 Image: Second system
 Image: Second system</t

## **INDICATOR 42 | KAP (PRACTICES)**

### ✓ ESTABLISHED

# PERCENTAGE OF HIVST USERS WHO HAVE CONFIDENCE TO PERFORM HIVST



### **PURPOSE**

Measuring effectiveness of information/ education campaign or of provider skills (based on program activities).

0	
~	

### DATA SOURCE

Periodic surveys (either representative or snap shots such as client satisfaction surveys). PSI's SHIPS project collects this through opt-in chatbot surveys sent to consumers who access information on how to use a HIVST through the chatbot.

	25	
1		

### WHERE IT'S BEING USED

PSI's Strengthening HIVST in the Private Sector (SHIPS) project.



### HOW IT'S CALCULATED

**Numerator:** Number of people reporting they feel well prepared to conduct a HIVST based on the information received

**Denominator:** Number of people surveyed

**Calculation of percentage:** Numerator ÷ denominator X 100

9
l

# EXAMPLE OF USE FOR DECISION MAKING

Data used to revise IEC materials, communication channels, or other aspects of an outreach campaign.



## **INDICATOR 43 | KAP (PRACTICES)**

### ✓ ESTABLISHED

# PERCENTAGE OF PEOPLE WHO HAVE SELF-TESTED AT TESTING SITES



### PURPOSE

Understanding whether people prefer to self-test on site as they might require help from the provider, or whether people are confident to test on their own and take the test kit off site.




## HOW IT'S CALCULATED

**Numerator:** Number of people reporting that they obtained an HIVST kit and self- tested on site

**Denominator:** Number of people who obtained an HIVST kit at testing sites

## Calculation of percentage:

Numerator ÷ denominator X 100



## **INDICATOR 44 | KAP (PRACTICES)**

### ✓ ESTABLISHED

# PERCENTAGE OF HIVST USERS WHO REPORT USING AT LEAST ONE OTHER SELF-CARE PRODUCT IN THE LAST 6 MONTHS

d
<u>()</u>

## PURPOSE

Capturing the growth of the overall self-care market.

	$\frown$	
(	Ч	

## DATA SOURCE

Surveys (either opt-in self-report or wider, more representative surveys). Other methods of collecting growth of the overall self-care market (such as reviewing sales logs) have proven difficult or impossible in the private sector.



## WHERE IT'S BEING USED

PSI's Strengthening HIVST in the Private Sector (SHIPS) project.



### HOW IT'S CALCULATED

**Numerator:** Number of people who report use of an additional self-care product (from a list of choices) in the past 6 months

**Denominator:** Number of people in the sample

**Calculation of percentage:** Numerator ÷ denominator X 100




### EXAMPLE OF USE FOR DECISION MAKING

HIVST offers the potential to promote health autonomy through concurrent promotion of other self-care products. This indicator measures if cross-selling/ up-selling other self-care activities is effective.




# INDICATOR 45 I SERVICE DELIVERY AND HEALTH OUTCOMES < ESTABLISHED NUMBER OF HIVST KITS DISTRIBUTED



## **INDICATOR 46 | SERVICE DELIVERY AND HEALTH OUTCOMES**


✓ ESTABLISHED

# PERCENTAGE OF HTS, ART, PREP AND VMMC CLINIC ATTENDEES USING HIVST



## **INDICATOR 47 | SERVICE DELIVERY AND HEALTH OUTCOMES** ✓ ESTABLISHED


NUMBER OF INDIVIDUALS SELF-TESTED FOR HIV, WHO SCREENED REACTIVE AND WHO RECEIVED CONFIRMED POSITIVE RESULT THROUGH PROVIDER RDT TESTING



## INDICATOR 48 | SERVICE DELIVERY AND HEALTH OUTCOMES 🗸 🗸 E

### ✓ ESTABLISHED


# NUMBER OF NEW POSITIVE TESTS WHO REPORT SELF-TEST USE



## INDICATOR 49 | SERVICE DELIVERY AND HEALTH OUTCOMES

#### ✓ ESTABLISHED

# NUMBER OF PEOPLE NEWLY ENROLLED ON ANTIRETROVIRAL THERAPY WHO REPORT SELF-TEST USE



SELF-MANAGED ABORTION INDICATORS

# SELF-MANAGED ABORTION INDICATORS

50.	Protocols for comprehensive abortion care aligned with global standards are in national medical/treatment guidelines	75	$\rightarrow$
51.	Percentage of accredited educational institutions for all relevant cadres with a competency-based SRHR component in pre-service curricula, consistent with global normative guidance	76	$\rightarrow$
52.	Country has system for in-service competency-based training in comprehensive abortion care (CAC) including SMA, for all recommended cadres of providers, consistent with global normative guidance	77	$\rightarrow$
53.	National Essential Medicines List includes combination mifepristone and misoprostol, or misoprostol and mifepristone as separate presentations	78	$\rightarrow$
54.	Number of quality-assured medical abortion products registered and available	79	$\rightarrow$
55.	Percentage of health providers who know the clinical policies prohibiting reporting of SMA clients to authorities	80	$\rightarrow$
56.	Percentage of individuals who understand what to expect at each step of the self-managed abortion process	81	$\rightarrow$
57.	Percentage of clients who felt prepared for what to do if they experienced warning signs or in the event of complications	82	$\rightarrow$
58.	Percentage of individuals who received quality medications from a reliable source or knew where to obtain them	83	$\rightarrow$
59.	Percentage of respondents who reported that services were affordable	84	$\rightarrow$
60.	Percentage of respondents who felt their pain was managed effectively	85	$\rightarrow$
61.	Percentage of respondents who reported feeling prepared to determine if their abortion was complete	86	$\rightarrow$

SEXUAL & REPRODUCTIVE HEALTH SELF-CARE MEASUREMENT TOOL

En	abling Environment       Knowledge, attitudes & practices       Service delivery	& health oi	utcomes
62.	Percentage of respondents who report trusting their provider(s)/ pharmacist(s) to keep their personal information confidential	87	$\rightarrow$
63.	Percentage of respondents who report they were treated with respect at all times	88	$\rightarrow$
64.	Percentage of individuals that do not feel judged for seeking follow up care during/after self-managed abortion	89	$\rightarrow$
65.	Percentage of individuals who desire follow-up care for any reason are able to obtain timely desired care	90	$\rightarrow$
66.	Percentage of SMA users seeking follow-up care who receive appropriate medical treatment	91	$\rightarrow$
67.	Percentage of SMA users who are no longer pregnant	92	$\rightarrow$
68.	Individual has a complete abortion without surgical intervention	93	$\rightarrow$
69.	Proportion of individuals with moderate or severe complications	94	$\rightarrow$

### **INDICATOR 50 | ENABLING ENVIRONMENT**

#### ✓ ESTABLISHED

# PROTOCOLS FOR COMPREHENSIVE ABORTION CARE ALIGNED WITH GLOBAL STANDARDS ARE IN NATIONAL MEDICAL/TREATMENT GUIDELINES



### PURPOSE

Identifying targets to strive for or maintain in the area of Governance and Policy Frameworks.

Existence of policy, strategy, or plan for improvement of quality and safety.



#### HOW IT'S CALCULATED

Qualitative assessment of deviations from WHO abortion guidelines with respect to the provision of quality abortion care.



# DATA SOURCE

Nationally available official government documents; abortion care standards and guidelines; Global Abortion Policies Database (GAPD).



### WHERE IT'S BEING USED


GAPD (https://abortion-policies.srhr.org/)

WHO/HRP multi-country initiative health system monitoring



#### EXAMPLE OF USE FOR DECISION MAKING

If protocols for comprehensive abortion care in national medical/treatment guidelines do not exist in the country or are not aligned with global standards, steps should be taken to develop protocols in national medical/ treatment guidelines for comprehensive abortion care that do align with global standards.



# **INDICATOR 51 | ENABLING ENVIRONMENT**

#### **X** NOT ESTABLISHED

PERCENTAGE OF ACCREDITED EDUCATIONAL INSTITUTIONS FOR ALL RELEVANT CADRES WITH A COMPETENCY-BASED SRHR COMPONENT IN PRE-SERVICE CURRICULA, CONSISTENT WITH GLOBAL NORMATIVE GUIDANCE



#### PURPOSE

Identifying targets to strive for or maintain in area of health workforce.



### DATA SOURCE

National lists of health educational institutions for each cadre

Available curricula

Ministry of Education

Ministry of Higher Education

Ministry of Labour and Human Resources or

Special assessment (which would have feasibility implications).

# EXAMPLE OF USE FOR DECISION MAKING

A low proportion indicates a need for more accredited education institutions for all relevant cadres with a competency-based SRHR component in pre-service curricula (inclusive of safe abortion/SMA/postabortion care/family planning), consistent with global normative guidance.



# HOW IT'S CALCULATED

**Numerator:** All accredited health education institutions nationally for health worker cadres engaged in providing SRH services with a competency-based SRHR component in the curricula (inclusive of SA/SMA/PAC/FP), consistent with global normative guidance

**Denominator:** All accredited health education institutions nationally for health worker cadres engaged in providing SRH services

#### Calculation of percentage:

Numerator ÷ denominator X 100



# STATUS OF DEVELOPMENT

Adapted from WHO/HRP multi-country initiative health system monitoring.

New: Specify SMA included in SRHR curricula. Monitor curricula for all 'relevant cadre' eligible to facilitate SMA, including those not typically based in health facilities.



# **INDICATOR 52 | ENABLING ENVIRONMENT**

#### **X** NOT ESTABLISHED

COUNTRY HAS SYSTEM FOR IN-SERVICE COMPETENCY-BASED TRAINING IN COMPREHENSIVE ABORTION CARE (CAC) INCLUDING SMA, FOR ALL RECOMMENDED CADRES OF PROVIDERS, CONSISTENT WITH GLOBAL NORMATIVE GUIDANCE



#### PURPOSE

Identifying targets to strive for or maintain in area of health workforce. National systems for continuing professional development.



# HOW IT'S CALCULATED

Qualitative assessment.



#### DATA SOURCE

National health workforce policy, strategy and planning documents.



# EXAMPLE OF USE FOR DECISION MAKING


If country does not have system for in-service competency-based training in comprehensive abortion care (CAC) including SMA, consistent with global normative guidance, this needs to be developed.



#### STATUS OF DEVELOPMENT

Adapted from WHO/HRP multi-country initiative health system monitoring.

Specify that SMA is included in inservice competency-based CAC training. Monitor availability of in-service SMA training for all cadres eligible to facilitate SMA, including those cadres not typically based in health facilities.



# **INDICATOR 53 | ENABLING ENVIRONMENT**

#### ✓ ESTABLISHED

NATIONAL ESSENTIAL MEDICINES LIST INCLUDES COMBINATION MIFEPRISTONE AND MISOPROSTOL, OR MISOPROSTOL AND MIFEPRISTONE AS SEPARATE PRESENTATIONS



#### PURPOSE

Identifying targets to strive for or maintain in area of medicines and other health products.



HOW IT'S CALCULATED

Qualitative assessment.



### DATA SOURCE

National essential medicines list; GAPD; IPPF Medical Abortion Commodities Database.

l

# EXAMPLE OF USE FOR DECISION MAKING

National Essential Medicines List includes combination mifepristone and misoprostol, or misoprostol and mifepristone as separate presentations.



#### WHERE IT'S BEING USED

GAPD; IPPF Medical Abortion Commodities Database

WHO/HRP multi-country initiative health system monitoring

 Image: Second system
 FREQUENCY

 NON-ROUTINE
 MONTHLY
 QUARTERLY
 ANNUALLY

# **INDICATOR 54 | ENABLING ENVIRONMENT**

#### ✓ ESTABLISHED

# NUMBER OF QUALITY-ASSURED MEDICAL ABORTION PRODUCTS REGISTERED AND AVAILABLE

C	PURPOSE Identifying targets to strive for or maintain in the area of medicines and other health products. Specifically, availability of essential medicines.	HOW IT'S CALCULATED Qualitative assessment of number of quality assured medical abortion products registered and available (combination mifepristone and misoprostol and / or misoprostol and mifepristone as separate presentations).
9	DATA SOURCE Information from National Medicines Regulatory Authority.	<b>WHERE IT'S BEING USED</b> IPPF Medical Abortion Commodities Database
i	<b>EXAMPLE OF USE FOR</b> <b>DECISION MAKING</b> To assure that quality-assured medical abortion products are registered and available.	WHO/HRP multi-country initiative health system monitoring
	FREQUENCY       NON-ROUTINE     MONTHLY     Q	UARTERLY ANNUALLY BIENNIALLY

### **INDICATOR 55 | ENABLING ENVIRONMENT**

#### **X** NOT ESTABLISHED

# PERCENTAGE OF HEALTH PROVIDERS WHO KNOW THE CLINICAL POLICIES PROHIBITING REPORTING OF SMA CLIENTS TO AUTHORITIES



#### **PURPOSE**

Evaluating policies that prevent providers from reporting clients for self-managed abortion, which is important to ensure that individuals do not face legal risk for SMA and/or there is larger support for SMA.




#### HOW IT'S CALCULATED

**Numerator:** Number of health providers who know the policy and have never reported SMA clients to authorities

**Denominator:** Number of health providers

**Calculation of percentage:** Numerator ÷ denominator X 100



### **INDICATOR 56 | KAP (KNOWLEDGE)**

#### ✓ ESTABLISHED

PERCENTAGE OF INDIVIDUALS WHO UNDERSTAND WHAT TO EXPECT AT EACH STEP OF THE SELF-MANAGED ABORTION **PROCESS** 



#### PURPOSE

Facilitating quality abortion care requires a person-centered approach to services; ensuring client understanding of what to expect throughout their abortion visit/call will contribute to preparedness and build trust in the provider-client relationship.




#### HOW IT'S CALCULATED

Numerator: Number of respondents who respond affirmatively to a question about understanding each step of the SMA process

Denominator: Number of respondents

Calculation of percentage: Numerator ÷ denominator X 100



**BIENNIALLY** 

# **INDICATOR 57 | KAP (ATTITUDES)**

#### ✓ ESTABLISHED

# PERCENTAGE OF CLIENTS WHO FELT PREPARED FOR WHAT TO DO IF THEY EXPERIENCED WARNING SIGNS OR IN THE EVENT OF COMPLICATIONS



### PURPOSE

Facilitating quality abortion care requires a person-centered approach to services; client knowledge about what to do following warning signs or adverse events suggests effective communication from the site and preparedness and support for the client. Preparedness may contribute to the prevention of potential negative health effects following abortion.



#### HOW IT'S CALCULATED

**Numerator:** Number of respondents who respond affirmatively to the question "Do you feel that you know what to do if you experience a warning sign of a complication?"

**Denominator:** Number of respondents

Calculation of percentage:

Numerator ÷ denominator X 100

*NB: Meets quality threshold if 90% of respondents report feeling prepared for what to do if they experienced warning signs or in the event of complications.* 



# **INDICATOR 58 | KAP (ATTITUDES OR PRACTICES)**

#### ✓ ESTABLISHED

# PERCENTAGE OF INDIVIDUALS WHO RECEIVED QUALITY MEDICATIONS FROM A RELIABLE SOURCE OR KNEW WHERE TO OBTAIN THEM

2
<u>s</u>

### PURPOSE

Facilitating quality abortion care requires that clients perceive their medications to be of high quality in order to instill confidence in the medical abortion process.



# HOW IT'S CALCULATED

**Numerator:** Number of respondents who respond affirmatively to the question "Did you obtain quality medications from a reliable source?". Or, if they have not yet obtained medications "do you know of a reliable source where you can obtain quality medications?"

**Denominator:** Number of respondents

**Calculation of percentage:** Numerator ÷ denominator X 100

8

#### WHERE IT'S BEING USED

ACQTool, indicator #4 (<u>https://www.</u> acqtool.org/metric/indicators/)

ANNUALLY

Ð

NON-ROUTINE

DATA SOURCE

FREQUENCY

ACQTool.

QUAR

MONTHIY

QUARTERLY

BIENNIALLY

# **INDICATOR 59 | SERVICE DELIVERY AND HEALTH OUTCOMES** × NOT ESTABLISHED

# PERCENTAGE OF RESPONDENTS WHO REPORTED THAT SERVICES WERE AFFORDABLE

Ċ

#### PURPOSE

Facilitating quality SMA requires affordable medications or follow up care for clients of all economic backgrounds.



# HOW IT'S CALCULATED

**Numerator:** Number of respondents who reported services were affordable

**Denominator:** Number of respondents

**Calculation of percentage:** Numerator ÷ denominator X 100

*NB: meets quality threshold if 100% of respondents report that services were affordable.* 

Q	DATA SOURCE Periodic surveys conducted by model(s) of care, or could be conducted by MOH.	STATUS OF DE Field-tested & valid ASQ project ACQTool, indicator acqtool.org/metric	ated as part of #7 ( <u>https://www.</u>
1	FREQUENCY       NON-ROUTINE       MONTHLY       QU	ARTERLY ANNUALLY	BIENNIALLY

# **INDICATOR 60 | SERVICE DELIVERY AND HEALTH OUTCOMES** × NOT ESTABLISHED

# PERCENTAGE OF RESPONDENTS WHO FELT THEIR PAIN WAS MANAGED EFFECTIVELY



#### PURPOSE

Facilitating quality SMA requires that individuals perceive effective management of pain during and after an abortion. Effective pain management can reduce anxiety, pain, and discomfort.




#### HOW IT'S CALCULATED

**Numerator**: Number of respondents who believe that their pain was effectively managed

**Denominator:** Number of respondents

**Calculation of percentage:** Numerator ÷ denominator X 100

NB: Meets quality threshold if 90% or more of respondents report believing that their pain was effectively managed.



### **INDICATOR 61 | SERVICE DELIVERY AND HEALTH OUTCOMES** × NOT ESTABLISHED

# PERCENTAGE OF RESPONDENTS WHO REPORTED FEELING PREPARED TO DETERMINE IF THEIR ABORTION WAS COMPLETE



#### PURPOSE

Facilitating quality SMA requires information and support about abortion completeness. This includes effective communication and preparedness.



#### HOW IT'S CALCULATED

**Numerator:** Number of respondents who report feeling prepared to determine if their abortion was complete

**Denominator:** Number of respondents

Calculation of percentage:

Numerator ÷ denominator X 100

NB: meets quality threshold if 90% of respondents report feeling prepared to determine when their abortion was complete.

Q

### DATA SOURCE

Periodic surveys conducted by model(s) of care, or could be conducted by MOH.

# **E**77

# STATUS OF DEVELOPMENT

Field-tested & validated as part of ASQ project

ACQTool, indicator #24 (<u>https://www.acqtool.org/metric/indicators/</u>)



NON-ROUTINE

FREQUENCY

QUARTERLY

MONTHIY

ANNUALLY

BIENNIALLY

### **INDICATOR 62 | SERVICE DELIVERY AND HEALTH OUTCOMES** × NOT ESTABLISHED

# PERCENTAGE OF RESPONDENTS WHO REPORT TRUSTING THEIR PROVIDER(S)/ PHARMACIST(S) TO KEEP THEIR PERSONAL INFORMATION CONFIDENTIAL



#### PURPOSE

Facilitating quality SMA suggests that individual's information is maintained private, therefore increasing trust and reducing stigma.



### HOW IT'S CALCULATED

**Numerator:** Number of respondents who report trusting their provider(s)/ pharmacist(s) to keep their personal information confidential

**Denominator:** Number of respondents

**Calculation of percentage:** Numerator ÷denominator X 100

NB: Meets quality threshold if 90% of respondents report trusting that their providers would keep their personal information confidential.

DATA SOURCE Periodic surveys conducted by model(s) of care, or could be conducted by MOH.		<b>STATUS OF DEVELOPMENT</b> Field-tested & validated as part of ASQ project ACQTool, indicator #28 ( <u>https://www. acqtool.org/metric/indicators/</u> )
FREQUENCY NON-ROUTINE MONTHLY Q	UARTERLY	ANNUALLY BIENNIALLY

### **INDICATOR 63 | SERVICE DELIVERY AND HEALTH OUTCOMES** × NOT ESTABLISHED

# PERCENTAGE OF RESPONDENTS WHO REPORT THEY WERE TREATED WITH RESPECT AT ALL TIMES

Ct
$\sim$

#### PURPOSE

Facilitating quality SMA requires that whenever a person interacts with the healthcare system during their abortion, they are treated with respect and dignity.



#### HOW IT'S CALCULATED

**Numerator:** Number of respondents who report they were treated with respect at all times

**Denominator:** Number of respondents

**Calculation of percentage:** Numerator ÷ denominator X 100

NB: Meets quality threshold if 90% of respondents report feeling that they were treated with respect at all times.

OATA SOURCE Periodic surveys conducted by model(s) of care, or could be


conducted by MOH.

# **E**73

# STATUS OF DEVELOPMENT

Field-tested & validated as part of ASQ project

ACQTool, indicator #29 (<u>https://www.</u> acqtool.org/metric/indicators/)



### **INDICATOR 64 | SERVICE DELIVERY AND HEALTH OUTCOMES** × NOT ESTABLISHED

# PERCENTAGE OF INDIVIDUALS THAT DO NOT FEEL JUDGED FOR SEEKING FOLLOW-UP CARE DURING/AFTER SELF-MANAGED ABORTION



#### **PURPOSE**

Establishing linkages to follow-up care when desired/needed is an important aspect of SMA. Individuals may not seek care if they perceive they will experience judgement/stigma or legal consequences.



#### HOW IT'S CALCULATED


**Numerator:** Number of respondents who do not feel judged for seeking follow up care during/after selfmanaged abortion

**Denominator:** Number of respondents

Calculation of percentage:


Numerator ÷ denominator X 100

NB: Meets quality threshold if 90% of respondents report feeling that they were not judged by providers during care seeking for their SMA.



# **INDICATOR 65 | SERVICE DELIVERY AND HEALTH OUTCOMES** × NOT ESTABLISHED

# PERCENTAGE OF INDIVIDUALS WHO DESIRE FOLLOW-UP CARE FOR ANY REASON ARE ABLE TO OBTAIN TIMELY DESIRED CARE



### **INDICATOR 66 | SERVICE DELIVERY AND HEALTH OUTCOMES** × NOT ESTABLISHED

# PERCENTAGE OF SMA USERS SEEKING FOLLOW-UP CARE WHO RECEIVE APPROPRIATE MEDICAL TREATMENT



#### PURPOSE

Ensuring that SMA users receive followup care appropriate to their care seeking reasons/needs (e.g., no unnecessary surgical intervention, ultrasound when requested for confirmation of completion, additional doses of miso, only recommended procedural methods (no sharp curettage).




#### HOW IT'S CALCULATED

**Numerator:** Number of SMA users who receive appropriate medical treatment


**Denominator**: Number of SMA users who seek follow-up care

**Calculation of percentage:** Numerator ÷ denominator X 100




# **INDICATOR 67 | SERVICE DELIVERY AND HEALTH OUTCOMES** × NOT ESTABLISHED

# PERCENTAGE OF SMA USERS WHO ARE NO LONGER PREGNANT




# **INDICATOR 68 | SERVICE DELIVERY AND HEALTH OUTCOMES** × NOT ESTABLISHED

# INDIVIDUAL HAS A COMPLETE ABORTION WITHOUT SURGICAL INTERVENTION



# **INDICATOR 69 | SERVICE DELIVERY AND HEALTH OUTCOMES** × NOT ESTABLISHED

# PROPORTION OF INDIVIDUALS WITH MODERATE OR SEVERE COMPLICATIONS



# ANNEX 1: ACRONYMS

AC	Access Collaborative
AIS	AIDS Indicator Survey
ACQ	Abortion Care Quality
ART	Antiretroviral Therapy
BMGF	Bill & Melinda Gates Foundation
CAC	Comprehensive abortion care
CE	Conformité Européenne (European Conformity)
CEPED	Centre Population & Développement (France)
CHAI	Clinton Health Access Initiative
CHW	Community Health Workers
CIFF	Children's Investment Fund Foundation
DHS	Demographic and Health Survey
DHIS2	District Health Information Software
DMPA-IM	Intramuscular depot medroxyprogesterone acetate
DMPA-SC	Subcutaneous depot medroxyprogesterone acetate
ELWG	Evidence and Learning Working Group
EPIC	Meeting Targets and Maintaining Epidemic Control project
ERPD	Expert Review Panel for Diagnostics
EVIHDAF	Evidence for Sustainable Human Development Systems in Africa
FDA	Food and Drug Administration
FHI	360 Family Health International
FP	Family Planning
GAM	Global AIDS Monitoring Survey
GAPD	Global Abortion Policies Database
GFPVAN	Global Family Planning Visibility and Analytics Network
GIWYN	Generation Initiative for Women and Youth Network
HIPS	Family Planning High Impact Practices
HIS	Health Information System
HIV	Human immunodeficiency virus
HIVST	HIV self-testing
HMIS	Health Management Information System

#### SEXUAL & REPRODUCTIVE HEALTH FIRST EDITION SELF-CARE MEASUREMENT TOOL FEBRUARY 2023

HRP	Human Reproduction Programme
HTS	HIV testing services
IEC	Information, Education and Communication
IHRIS	Human Resources Information System
INED	Institut National d'Etudes Démographiques (France)
IPPF	International Planned Parenthood Federation
КАР	Knowledge, Attitudes and Practices
LMIS	Logistic management information systems
MAKSPH	Makerere University School of Public Health (Uganda)
MEWG	Measurement Expert Working Group
M&E	Monitoring and evaluation
MOE	Ministry of Education
МОН	Ministry of Health
NRA	National regulatory approval
NSN	National Self-Care Network
PAC	Postabortion care
PEPFAR	President's Emergency Plan for AIDS Relief
РМА	Performance Monitoring for Action
PQ	Prequalification
PQED	Pre-qualified
PREP	Pre-exposure prophylaxis
PSI	Population Services International
RDT	Rapid diagnostic test
SA	Safe abortion
SCARU	Self-Care Academic Research Unit (UK)
SCEG	Self-Care Expert Group
SCTG	Self-Care Trailblazer Group
SDPS	Service delivery points
SEED	Supply-Enabling Environment-Demand (Model for Family Planning Programming)
SHIPS	Strengthening HIV Self-Testing in the Private Sector
SI	Self-injectable
SMA	Self-managed abortion
SRA	Stringent Regulatory Authority

SRH	Sexual and reproductive health
SRHR	Sexual and Reproductive Health and Rights
STAR	HIV Self-Testing Africa
TGA	Therapeutic Goods Administration (Australia)
TWG	Technical Working Group
TX_NEW	Number of adults and children newly enrolled on antiretroviral therapy
UCSF	University of California, San Francisco
UN	United Nations
UNAIDS	Joint United Nations Programme on HIV/AIDS
UNDP	United Nations Development Programme
UNICEF	United Nations Children's Fund
VMMC	Voluntary Medical Male Circumcision
WHO	World Health Organization

 $\bullet \bullet \bullet \bullet \bullet \bullet \bullet \bullet \bullet$ 

• • • • • • • • • •

•

• •

• •

